New data show Moderna's experimental mRNA cancer vaccine reduces melanoma recurrence by 42% in advanced cases.
The therapy, known as intismeran, pairs with Merck's existing checkpoint inhibitor to prevent mid- to late-stage tumors from returning after initial treatment.
This milestone validates a scientific platform once dismissed as too unstable to support new medicines, a gamble that previously generated billions during the pandemic and secured approval for a seasonal mRNA flu shot earlier this year.
The company navigates canceled government contracts and workforce reductions alongside rising political skepticism surrounding the technology, with FDA review for the cancer treatment anticipated next year.